Real-world use of hybrid closed-loop insulin delivery is associated with improved glycemic control and sleep quality, as well as reduced fear of hypoglycemia in children and young people with type 1 diabetes, shows a UK study.
Delayed prandial insulin boluses are common in people using advanced technologies for the management of type 1 diabetes and are associated with adverse glycemic outcomes, suggest real-world study results.
Starting young people on closed-loop insulin delivery within 21 days after type 1 diabetes diagnosis does not slow the decline in their C-peptide levels over the next 12 months, report the CLOuD investigators.
Use of the MiniMed 780G advanced hybrid closed-loop system leads to greater reductions in glycated hemoglobin levels than conventional treatment in people with poorly controlled type 1 diabetes, ADAPT study data show.
Improved glycemic control with hybrid closed-loop insulin delivery may facilitate the typical neurodevelopmental changes that occur during adolescence for those with type 1 diabetes, suggests a proof-of-concept trial.
Use of the Tandem Control IQ hybrid closed-loop insulin delivery system improves time in range even for users who very rarely bolus for meals or to treat hyperglycemia, an observational study suggests.
Children and adolescents using an advanced hybrid closed-loop system for type 1 diabetes can tolerate an unannounced snack containing 20 g of carbohydrate without excessive blood sugar fluctuations, Italian researchers report.